OVARIAN CANCER and US: votrient

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Showing posts with label votrient. Show all posts
Showing posts with label votrient. Show all posts

Saturday, July 17, 2010

Drug Watch a heads-up on pharmaceuticals in late-stage development



New drugs Product type/proposed indication FDA status/notes

abagovomab
Menarini Group
an anti-idiotype antibody, able to mimic a tumor antigen
highly expressed by ovarian cancer cells/used to prevent
or delay the tumor relapse in patients whose disease
responded to the first-line chemotherapy by activating
an immune response toward cancer cells
phase 2/3

karenitecin/BNP1350
BioNumerick Pharmecuticals
in the camptothecin class of chemotherapy drugs/
treatment of advanced ovarian cancer
phase 3

pazopanib (Votrient)
GlaxoSmithKline
multi-kinase angiogenesis inhibitor/maintenance therapy
for the treatment of ovarian cancer
phase 3
 references/sources: